TG Therapeutics (TGTX)
NASDAQ:TGTX
Want to see TGTX full AI Analyst Report?
Earnings Data
Report Date
Aug 10, 2026TBA (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
0.33Last Year’s EPS
0.17Same Quarter Last Year
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed strong, tangible commercial momentum: record Q1 revenue, 63% YoY U.S. growth, rising patient counts (25,000+), improved profitability, a robust cash position and aggressive share buybacks. Management also highlighted multiple near‑term clinical catalysts (ENHANCE, subcutaneous readouts) and longer‑term expansion opportunities (subcutaneous formulation, additional indications). Offsetting this optimism are near‑term expense increases (including ~$100M subcutaneous spend), a one‑time refinancing charge, notable gross‑to‑net/rebate pressure (~65% guidance), and clinical/regulatory timing and outcome risks for key lifecycle programs and the azer‑cel program. Overall, the positives (strong revenue beats, guidance raises, cash and buybacks, lifecycle catalysts, and supportive long‑term data) materially outweigh the listed challenges, though execution and trial outcomes remain critical to sustaining the trajectory.Company Guidance
Record Revenue and Guidance Upside
U.S. BRIUMVI net product revenue of ~$195M in Q1, above guidance of $185M–$190M and up 63% year-over-year; global revenue exceeded $200M and total revenue was $205M (including $3.6M license/royalty). Company raised full-year U.S. revenue guidance to $885M–$900M, full-year global revenue guidance to ~$925M, and is targeting Q2 U.S. revenue of ~ $220M. Management expects to approach a $1B annualized run rate before year-end.
Strong Profitability and Liquidity
Operating income of $34.8M in Q1 versus $8.6M a year ago (≈305% increase). Net income was $19.8M ($0.12/diluted) vs $5.1M ($0.03) a year ago (≈288% increase). Cash, cash equivalents and investment securities ended Q1 at ~$573M, up from roughly $200M at year-end (~186% increase), providing financial flexibility.
Robust Commercial Momentum and Patient Adoption
More than 25,000 patients prescribed BRIUMVI globally. Company reported its 12th consecutive quarter of sequential growth since launch, record new patient enrollments in Q1 with March the highest month ever, and an increasing mix of treatment‑naive patients—signaled as the strongest leading indicator for long-term share.
Near-Term Clinical Catalysts and Lifecycle Expansion
Phase III ENHANCE topline data (consolidated dosing eliminating day-15 infusion) and Phase I bioavailability data expected in the coming weeks. Subcutaneous Phase III study is fully enrolled with topline data expected year-end/early next year and a potential 2028 commercial launch if positive — a program management expects could nearly double the addressable market by enabling participation in both IV and subcutaneous anti-CD20 segments.
Strong Real-World and Long-Term Clinical Data
Five‑year follow-up data from ULTIMATE I & II open‑label extension published in JAMA Neurology demonstrating sustained efficacy and consistent safety/tolerability. AAN real-world data showed rapid, sustained B‑cell depletion, low annualized relapse rates, favorable infusion experience, and improvement in patient‑reported 'wearing off' after switching to BRIUMVI.
Disciplined Capital Allocation and Share Repurchases
Expanded Blue Owl financing to enhance flexibility; repurchased ~$100M of stock during the quarter (over 3M shares at ~ $30 average). Since program launch, repurchased ~6.8M shares at ~ $29 average (~5% of shares outstanding), while remaining opportunistic on business development.
Pipeline Diversification Beyond Relapsing MS
Advancing additional programs including planned Phase II (potentially registration‑directed) in myasthenia gravis, an exploratory study in treatment‑resistant schizophrenia, and progress on allogeneic anti‑CD19 CAR‑T (azer‑cel) in progressive MS — with clinical sites expressing higher demand than available slots.
Revenue Growth Outpacing Expense Growth with Clear Guidance
Q1 OpEx (R&D + SG&A, ex stock comp) was ~$117M while management stated revenue growth continues to outpace expense growth. Reiterated full-year OpEx guidance of ~ $350M (ex stock comp) plus ~$100M for subcutaneous manufacturing/secondary manufacturer start-up, showing a planning framework for near-term investments.
TGTX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
TGTX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 06, 2026 | $36.10 | $41.97 | +16.26% |
Feb 26, 2026 | $29.66 | $30.90 | +4.18% |
Nov 03, 2025 | $34.78 | $33.69 | -3.13% |
Aug 04, 2025 | $35.02 | $28.72 | -17.99% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does TG Therapeutics (TGTX) report earnings?
TG Therapeutics (TGTX) is schdueled to report earning on Aug 10, 2026, TBA (Confirmed).
What is TG Therapeutics (TGTX) earnings time?
TG Therapeutics (TGTX) earnings time is at Aug 10, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TGTX EPS forecast?
TGTX EPS forecast for the fiscal quarter 2026 (Q2) is 0.33.